Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00297180 · ClinicalTrials.gov registry record · Phase 2
Weight Loss In Obese Subjects Taking Either GW869682 Or Placebo 3 Times Per Day For 12 Weeks
A Phase 2 study of Obesity, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 136
- Enrollment target
- 3
- Study locations
NCT00297180: Completed Phase 2 study of Obesity, sponsored by GlaxoSmithKline.
NCT00297180 is a Phase 2 study of Obesity that has completed, run by GlaxoSmithKline. The registered enrollment target is 136 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (83% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00297180, a Phase 2 study of Obesity, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 136 participants
- Enrollment target
- 3
- Study locations
Study Summary
GW869682 causes glucose to be excreted in the urine. The purpose of this study is to see whether enough calories from glucose are excreted in the urine to cause weight loss.
Conditions Studied
Interventions
- DRUG GW869682
Study Locations (3)
Florida
- GSK Investigational Site - Daytona Beach
Louisiana
- GSK Investigational Site - Baton Rouge
Oregon
- GSK Investigational Site - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2006-01 |
| Est. Completion | 2006-09 |
| Phase | Phase 2 |
What the finished NCT00297180 record still lists
NCT00297180 is an interventional study that assigns participants to a tested intervention. The registered 136 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 1 intervention - of which GW869682 is the first listed.
NCT00297180 reports a single indexed study location in Florida, Louisiana, Oregon.
Frequently Asked Questions
What is clinical trial NCT00297180 about?
NCT00297180 is a clinical study titled "Weight Loss In Obese Subjects Taking Either GW869682 Or Placebo 3 Times Per Day For 12 Weeks". GW869682 causes glucose to be excreted in the urine. The purpose of this study is to see whether enough calories from glucose are excreted in the urine to cause weight loss.
What is the current status of trial NCT00297180?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 136 participants. The study started on 2006-01. Estimated completion is 2006-09.
What conditions does trial NCT00297180 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT00297180?
The interventions under investigation include: GW869682 (DRUG).
Who is sponsoring clinical trial NCT00297180?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00297180 being conducted?
This trial has 3 study locations across Florida, Louisiana, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00297180's enrollment target sits among peer trials
136 407th of 1053 higher than 641 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01555892 · 136 participants · Phase 1
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- NCT03216525 · 136 participants · Phase 3
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
- NCT04476901 · 136 participants · Phase 2
Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy
- NCT04603898 · 136 participants · NA
Oxalate Formation From Ascorbic Acid
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia